AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 31 min read$UTHR

MAHON PAUL A sold $4.0M of UTHR

MAHON PAUL A (EVP & GENERAL COUNSEL) sold 8,300 shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $482.03 ($478.93–$490.88, $4.00M total) across 11 trades on 2026-09-03 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · MAHON PAUL A
Published Sep 3, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 7:11 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$UTHR
Bearish
medium confidence
Mentioned
$UTHR
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$UTHRBearishLow
01

Why it matters

Direct insider sale may influence short‑term price dynamics.

02

Market read

Routine insider sale with modest size; limited trading relevance.

03

What to watch

Potential upcoming corporate actions or financing needs not disclosed.

Relevance 5/10Novelty 4/10Timing: same‑day filing

Background

Form 4 filing reports insider transaction for United Therapeutics (UTHR).

Company-level read

Ticker impact

$UTHRBearishMedium confidence
Context

EVP & General Counsel Paul Mahon sold 8,300 shares for $4.0M via a 10b5‑1 plan.

Expected impact

Potential short‑term dip of 1‑2% as market digests sale.

Evidence & confidence

Sale size is modest but disclosed via Form 4, indicating a direct insider divestment.

Market effects

Sector

Limited impact on biotech sector; typical insider sale.

Regional

Negligible effect on broader market.

Global

None

Counterpoint

What could challenge this read

Sale could be routine portfolio rebalancing, not a bearish signal.

Key entities

  • company
    United Therapeutics Corp

    Biopharma company listed on NYSE under ticker UTHR.

  • insider
    Paul Mahon

    EVP & General Counsel of United Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

UTHR insider trading history →

Related articles

SEP 10
$UTHRMed

Is United Therapeutics (UTHR) A Bargain Following Its Tyvaso FDA Acceptance?

United Therapeutics (UTHR) is under scrutiny after the FDA accepted its supplemental New Drug Application for Tyvaso in idiopathic pulmonary fibrosis. The company's stock has seen short-term declines, but long-term returns remain strong. Analysts suggest UTHR may be undervalued, with a fair value estimate of $665.23, citing its drug pipeline and innovation. However, risks include potential trial disappointments and competition.

simplywall.st2 min
SEP 9
$UTHRMed

United Therapeutics at Cantor healthcare conference: fibrosis push widens

United Therapeutics (UTHR) announced a strategic shift toward pulmonary fibrosis at the Cantor Fitzgerald Global Healthcare Conference, aiming for a 10-fold market expansion. The company presented strong clinical data for nebulized Tyvaso, with FDA review expected by April 2027. Management also announced a $500M stock repurchase and plans for 14 product launches through 2029, including new Tyvaso formulations and ralinepag products. The company projects a significant revenue opportunity in the p

investing.com3 min
SEP 9
$UTHRMedAI 8/10

Therapeutics Stocks Q2 Teardown: United Therapeutics (NASDAQ:UTHR) Vs The Rest

United Therapeutics (UTHR) stock rose 4.3% post-earnings, trading at $214.36. Myriad Genetics (MYGN) reported $190.7M revenue, down 10.5% YoY, missing estimates, and guidance fell short, causing a 40.9% stock drop to $3.18. Gilead Sciences (GILD) reported $7.8B revenue, up 10.2% YoY, beating estimates, with stock up 8.1% to $146.16. Novavax (NVAX) reported $56.7M revenue, down 76.3% YoY, but beat estimates, with stock up 32.2% to $10.18.

finance.yahoo.com3 min